Consistent with a role of AXL in RNASE4-induced prostate cancer growth, we found that RNASE4 knockdown or treatment with RNASE4 mAb in xenograft animal models resulted in a reduction of AXL phosphorylation without affecting the total AXL levels in the tumor tissues. Here, RNASE4 is linked to prostate cancer.